Kiniksa Pharmaceuticals International, plc KNSA
Set alert
90.80 USD -1.44 -1.56%
At close · Nov 2
91.50 +0.70 +0.77%
After hours · Nov 2, 4:00 PM ET
90.56 Day range 94.14
36.56 52-week range 98.48
- YTD
- +120.12%
- 1 year
- +145.34%
- Open
- 92.83
- Prev close
- 92.24
- Mkt cap
- 7.13B
- Vol
- 998.88K
- Avg vol
- 625.02K
- EPS
- 1.32
- P/E
- 68.79
- Div yield
- 0.00%
More statistics
- Low
- 90.56
- High
- 94.14
- Forward P/E
- 41.60
- Beta
- 0.08
- Short ratio
- 6.53
- Inst. own
- 101.31%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 79.16
- 200-d avg
- 60.21
- 1y target
- 109.43
3M chart
Events in this range
- Oct 27, 2026Earnings: 0.56; estimate 0.371; surprise 50.94%
- Oct 28, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 28, 2026Rating: Wedbush · Outperform → Outperform
- Oct 28, 2026Rating: Goldman Sachs · Buy → Buy
- Oct 30, 2026Rating: JP Morgan · Overweight → Overweight
Signals (19)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 7, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 13, 2026 | 2 months ago |
Key statistics
- Market cap
- 7.13B
- Enterprise value
- 6.69B
- Trailing P/E
- 68.79
- Forward P/E
- 41.60
- PEG ratio
- 0.00
- Price / sales
- 7.54
- Price / book
- 10.03
- EPS (TTM)
- 1.32
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 11.58%
- Revenue (TTM)
- 945.96M
- Revenue growth
- 58.10%
- Free cash flow
- 135.87M
- Total cash
- 568.76M
- Total debt
- 7.88M
- Return on equity
- 17.59%
- Shares outstanding
- 48.84M
- Short % of float
- 9.31%
- 50-day average
- 79.16
- 200-day average
- 60.21
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 109.43 +20.5% upside
Now 90.80
- Target (low)
- 98.00
- Target (mean)
- 109.43
- Target (high)
- 134.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.275.
Financials — quick view
KNSA Revenue — quarterly 285.97M
KNSA Net income — quarterly 47.34M
KNSA EPS — quarterly 0.61
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.25 | — | — | — |
| Oct 27, 2026 | Sep 30, 2026 | 0.371 | 0.56 | +0.19 | +50.94% |
| Jul 28, 2026 | Jun 30, 2026 | 0.2995 | 0.30 | 0.00 | +0.17% |
| Apr 28, 2026 | Mar 31, 2026 | 0.18 | 0.27 | +0.09 | +50.00% |
| Feb 24, 2026 | Dec 31, 2025 | 0.29 | 0.17 | -0.12 | -41.38% |
| Oct 28, 2025 | Sep 30, 2025 | 0.33 | 0.23 | -0.10 | -30.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 28, 2026 | Goldman Sachs | main | Buy | Buy |
| Oct 28, 2026 | Wedbush | main | Outperform | Outperform |
| Oct 28, 2026 | Wells Fargo | main | Overweight | Overweight |
| Jul 30, 2026 | Goldman Sachs | main | Buy | Buy |
| Jul 29, 2026 | JP Morgan | main | Overweight | Overweight |
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United Kingdom
- Website
- kiniksa.com
News
- JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
- Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101
- Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $102
- Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $110
- Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Crude Oil Moves Lower; Corning Earnings Top Views
- What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
- Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
- Pentair, JetBlue Airways, Hawkins And Other Big Stocks Moving Higher On Tuesday
Your note
Sign in to keep a note on KNSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Stock Award(Grant) | May 28, 2026 | 0 |
| BAKER BROTHERS LIFE SCIENCES, L.P. | Director | Stock Award(Grant) | Jun 2, 2025 | 0 |
| LEVY RICHARD S | Director | Conversion of Exercise of derivative security | Jul 30, 2026 | 22,359 |
| MALLEY THOMAS ROBERT | Director | Conversion of Exercise of derivative security | May 28, 2026 | 87,312 |
| MEGNA MICHAEL R | Officer | Sale | Sep 2, 2026 | 29,062 |
| MOAT ROSS | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 31, 2026 | 16,307 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 17.30% | 6,971,361 | 633.00M | Jun 29, 2026 |
| Rubric Capital Management LP | 9.92% | 3,999,800 | 363.18M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 7.03% | 2,834,643 | 257.39M | Jun 29, 2026 |
| Blackrock Inc. | 6.80% | 2,739,615 | 248.76M | Jun 29, 2026 |
| Tang Capital Management, LLC | 5.61% | 2,259,889 | 205.20M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.74% | 1,911,335 | 173.55M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.27% | 1,318,452 | 119.72M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.93% | 1,180,466 | 107.19M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 2.41% | 970,000 | 88.08M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 954,719 | 86.69M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.68% | 676,146 | 61.39M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.58% | 637,600 | 57.89M | Aug 30, 2026 |